OraSure Secures $7.5M Contract With $11M Potential for Marburg Virus Rapid Test Development
OraSure Secures $7.5M Contract With $11M Potential for Marburg Virus Rapid Test Development
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
OraSure Technologies, Inc. (纳斯达克:OSUR)是一家在现场和家庭诊断测试及样本管理解决方案方面的领导者，今天宣布通过快速反应伙伴关系工具（RRPV）获得了一项奖项，用于开发马尔堡病毒病（MVD）快速抗原检测。RRPV是一个由生物医药先进研究与发展局（BARDA）资助的财团，该局是美国卫生与公共服务部（HHS）战略准备与响应管理局（ASPR）的一部分。
The initial contract award, valued at approximately $7.5 million over multiple years in the base period with potential value up to $11 million, funds the development to achieve U.S. Food and Drug Administration (FDA) 510(k) clearance of a single-use lateral flow immunoassay intended for the qualitative detection of antigens from viruses within the Marburg virus genus. We expect that the proposed test will be intended for use with specimens from individuals with epidemiological risk factors who have signs or symptoms of MVD or from recently deceased individuals with epidemiological risk factors who are suspected to have died of MVD.
初始合同的授予价值约为750万美元，涵盖多个年度的基础期，潜在价值可达1100万美元，资金用于达到美国食品和药物管理局（FDA）510(k)的批准，目标是开发一种一次性侧流免疫测定法，用于定性检测来自马尔堡病毒属的病毒的抗原。我们预计，拟议的测试将用于从具有流行病学风险因素的个体中提取样本，这些个体有MVD的迹象或症状，或者是来自近期去世的具有流行病学风险因素，怀疑因MVD而死亡的个体。
